These included two CPI naïve patients (ESCC, 6 mg QW switched to 12 mg Q2W after 15 weeks treatment, DOR 75.7 weeks; and squamous cell carcinoma of unknown primary, 60 mg QW, DOR 23.3 weeks and continues on EMB-02 treatment off-study) The third patient with non-acral cutaneous melanoma, BRAF V600 wild type, had a total exposure duration of 42.9 weeks, DOR of 72.4 weeks and remains in CR at the time of study closure. The gene discussed is BRAF; the disease is esophageal squamous cell carcinoma.